We designed and tested over 100 improvements to our client’s instrument in just five months, enabling rapid iteration and scaled-up production. In addition, our team manufactured 45 units and generated the device history records needed to gain a CE Mark.
Catheter ablation is widely used to treat a range of abnormal heart rhythms. It involves passing a thin, flexible catheter through the blood vessels to the heart, where it pinpoints the arrhythmia and uses ablation to block the abnormal electrical signals. A more dexterous catheter increases success rates for patients and retains greater cardiac function.
We undertook the end-to-end development of the system’s hardware and communications backbone. We designed, built, and tested the system components and implemented Asian based manufacturing for a market trial in 300 apartments, all in just 12 months.
Seeking proof that consumers would follow novel usage instructions over time, Avon turned to diialog™ - our unique miniature sensing technology - to capture quantitative data during user tests.
We designed and manufactured an ingenious connected sensor to prove the monitoring technology to market leaders in home automation. The unrivalled performance and ease of use of the sensor, together with positive trial results led to a successful new product launch.
The cost effective system provides live horse racing data to smart phone betting apps. With infrastructure installed in 38 racetracks across the US and UK and with over 27,000 races broadcast, it is creating a growing business for our client.
We helped develop a new heart monitor to allow vets and trainers to accurately assess sport horses and spot anomalies that might indicate problems. It is now used all over the world to improve welfare in both training and in international competitions.
Testing early in the development cycle allows designs to mature more quickly. Our novel Digital Injection Moulding process provides accurate moulded parts in hours, which means we can reduce time to market and increase product quality.
Drug delivery devices can be notoriously tricky to use, so our technology enables improved studies that can distinguish use error from drug performance. This allows developers to focus investment correctly, reduce costs and accelerate a new treatment’s journey to market.
This autonomous device collects partially digested food samples from exact locations inside the canine gut. It enables our client to gain unique and important insight into canine digestion to advance both scientific knowledge and their strategic development capability.
Distributed sensors spot poacher activity over large remote areas and send threat alerts over a bespoke network to local wildlife rangers. Within 18 months the system was developed, prototyped and trialled in Kenya. It has won international acclaim and has enormous conservation potential.
The aim was to disrupt the diagnostics market with a lancing system that would significantly improve the patient’s experience. Our development and regulatory teams helped our client launch the first FDA & CE approved device for fully automated, virtually pain-free lancing.